Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

Haematologica

Volumn 99, Issue 8, 2014, Pages 1365-1372

  López Corral, Lucía ^a   Corchete, Luis Antonio ^a   Sarasquete, María Eugenia ^a   Mateos, María Victoria ^a   García Sanz, Ramón ^a   Fermiñán, Encarna ^b   Lahuerta, Juan José ^c   Bladé, Joan ^d   Oriol, Albert ^e   Teruel, Ana Isabel ^f   Martino, María Luz ^g   Hernández, José ^h   Hernández Rivas, Jesús María ^a   Burguillo, Francisco Javier ⁱ   San Miguel, Jesús F ^a   Gutiérrez, Norma C ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f Servicio de Hematología del Hospital Universitario de Valencia   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h HOSPITAL GENERAL DE SEGOVIA   (Spain)

ⁱ UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ATAXIN 2; ATM PROTEIN; CD81 ANTIGEN; CELL CYCLE PROTEIN 6; CYTOKINE; GLUCOCORTICOID RECEPTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN GADD45 ALPHA; IMMUNOGLOBULIN MU CHAIN; INITIATION FACTOR 2; INTERLEUKIN 16; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 7; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIPLE EGF LIKE DOMAIN 9; NUCLEIC ACID BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P53; RIBOSOMAL PROTEIN S10; RIBOSOMAL PROTEIN S12; RIBOSOMAL PROTEIN S17; RIBOSOMAL PROTEIN S28; SMALL NUCLEOLAR RNA; STRESS ACTIVATED PROTEIN KINASE; SYNDECAN 1; TRANSCRIPTOME; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VERSICAN CORE PROTEIN; ZINC FINGER PROTEIN;

APOPTOTIC PROTEASE ACTIVATING FACTOR 1 GENE; ARTICLE; CABLES GENE; CARCINOGENESIS; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; GENE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN TISSUE; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; RAC ALPHA SERINE THREONINE PROTEIN KINASE 1 GENE; RAC ALPHA SERINE THREONINE PROTEIN KINASE 2 GENE; REAL TIME POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; SMOLDERING MYELOMA; UPREGULATION; ADULT; AGED; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; PARAPROTEINEMIAS;

EID: 84905192557     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.087809     Document Type: Article

References (56)

1. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012; 12(5): 335-48.
2. Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D, et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol. 2005; 23(29): 7296-306.
3. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005; 23 (26): 6333-8.
4. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005; 106(1): 296-303.
5. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007; 67(7): 2982-9.
6. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 2005; 24(15): 2461-73.
7. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008; 112(10): 4235-46.
8. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113(22): 5412-7.
9. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009; 113(22): 5418-22.
10. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003; 102(13): 4504-11.
11. Hallek M, Leif Bergsagel P, Anderson KC. Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process. Blood. 1998; 91(1): 3-21.
12. Avet-Loiseau H, Li JY, Morineau N, Facon T, Brigaudeau C, Harousseau JL, et al. Monosomy 13 Is Associated With the Transition of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. Blood. 1999; 94(8): 2583-9.
13. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002; 99(6): 2185-91.
14. Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RKM, Stockley DM, et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica. 2009; 94 (12): 1708-13.
15. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust A, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002; 100 (4): 1417-24.
16. Kaufmann H, Ackermann J, Baldia C, Nosslinger T, Wieser R, Seidl S, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia. 2004; 18(11): 1879-82.
17. Lopez-Corral L, Gutierrez NC, Vidriales MB, Mateos MV, Rasillo A, Garcia-Sanz R, et al. The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells. Clin Cancer Res. 2011; 17(7): 1692-700.
18. Lopez-Corral L, Sarasquete ME, Bea S, Garcia-Sanz R, Mateos MV, Corchete LA, et al. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia. 2012; 26(12): 2521-9.
19. Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, et al. Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4; 14), Gain 1q, Hyperdiploidy, and Tumor Load. J Clin Oncol. 2013; 31(34): 4325-32.
20. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013; 27(8): 1738-44.
21. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011; 25(6): 1026-35.
22. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99(5): 1745-57.
23. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007; 109(4): 1692-700.
24. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5): 749-57.
25. Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez CL, et al. Lenalidomide plus dexamethasone for highrisk smoldering multiple myeloma. N Engl J Med. 2013; 369(5): 438-47.
26. Lopez-Corral L, Mateos MV, Corchete LA, Sarasquete MaE, de la Rubia J, de Arriba F, et al. Genomic analysis of high-risk smoldering multiple myeloma. Haematologica. 2012; 97(9): 1439-43.
27. Gutierrez NC, Sarasquete ME, MisiewiczKrzeminska I, Delgado M, De Las RJ, Ticona FV, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010; 24(3): 629-37.
28. Gutierrez NC, Ocio EM, De Las RJ, Maiso P, Delgado M, Ferminan E, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia. 2007; 21 (3): 541-9.
29. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001; 98(9): 5116-21.
30. Li M, Zhang Y, Zhai Q, Feurino LW, Fisher WE, Chen C, et al. Thymosin beta-10 is aberrantly expressed in pancreatic cancer and induces JNK activation. Cancer Invest. 2009; 27(3): 251-6.
31. Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002; 21(43): 6587-97.
32. Liebermann DA, Hoffman B. Gadd45 in the response of hematopoietic cells to genotoxic stress. Blood Cells Mol Dis. 2007; 39(3): 329-35.
33. Cesaro E, Montano G, Rosati A, Crescitelli R, Izzo P, Turco MC, et al. WT1 protein is a transcriptional activator of the antiapoptotic bag3 gene. Leukemia. 2010; 24(6): 1204-6.
34. Jourdan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J, et al. Gene expression of anti-and pro-apoptotic proteins in malignant and normal plasma cells. Br J Haematol. 2009; 145(1): 45-58.
35. Tarte K, Jourdan M, Veyrune JL, Berberich I, Fiol G, Redal N, et al. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. Br J Haematol. 2004; 125(3): 373-82.
36. Schmitt E, Naveau M, Mechulam Y. Eukaryotic and archaeal translation initiation factor 2: a heterotrimeric tRNA carrier. FEBS Lett. 2010; 584(2): 405-12.
37. Shin MH, Yuan M, Zhang H, Margolick JB, Kai M. ATM-dependent phosphorylation of the checkpoint clamp regulates repair pathways and maintains genomic stability. Cell Cycle. 2012; 11(9): 1796-803.
38. Wertheimer E, Gutierrez-Uzquiza A, Rosemblit C, Lopez-Haber C, Sosa MS, Kazanietz MG. Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell Signal. 2012; 24(2): 353-62.
39. Sperone A, Dryden NH, Birdsey GM, Madden L, Johns M, Evans PC, et al. The transcription factor Erg inhibits vascular inflammation by repressing NF-kappaB activation and proinflammatory gene expression in endothelial cells. Arterioscler Thromb Vasc Biol. 2011; 31(1): 142-50.
40. Wang Y, Cheong D, Chan S, Hooi SC. Ribosomal protein L7a gene is up-regulated but not fused to the tyrosine kinase receptor as chimeric trk oncogene in human colorectal carcinoma. Int J Oncol. 2000; 16(4): 757-62.
41. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 2002; 99(6): 2162-71.
42. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010; 277(19): 3904-23.
43. Cunha IW, Carvalho KC, Martins WK, Marques SM, Muto NH, Falzoni R, et al. Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol. 2010; 3(1): 23-32.
44. Mei YP, Liao JP, Shen JP, Yu L, Liu BL, Liu L, et al. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene. 2011; 31(22): 2794-804.
45. Dong XY, Guo P, Boyd J, Sun X, Li Q, Zhou W, et al. Implication of snoRNA U50 in human breast cancer. J Genet Genomics. 2009; 36(8): 447-54.
46. Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14. 3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet. 2008; 17(7): 1031-42.
47. Valleron W, Laprevotte E, Gautier EF, Quelen C, Demur C, Delabesse E, et al. Specific small nucleolar RNA expression profiles in acute leukemia. Leukemia. 2012; 26(9): 2052-60.
48. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, et al. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene. 2011; 30(11): 1329-40.
49. La Rocca R, Fulciniti M, Lakshmikanth T, Mesuraca M, Ali TH, Mazzei V, et al. Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells. J Immunol. 2009; 182(8): 4529-37.
50. Gyory I, Fejer G, Ghosh N, Seto E, Wright KL. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol. 2003; 170(6): 3125-33.
51. Tan D, Kirley S, Li Q, Ramnath N, Slocum HK, Brooks JS, et al. Loss of cables protein expression in human non-small cell lung cancer: a tissue microarray study. Hum Pathol. 2003; 34(2): 143-9.
52. Zhang H, Duan HO, Kirley SD, Zukerberg LR, Wu CL. Aberrant splicing of cables gene, a CDK regulator, in human cancers. Cancer Biol Ther. 2005; 4(11): 1211-5.
53. Tsukahara F, Maru Y. Bag1 directly routes immature BCR-ABL for proteasomal degradation. Blood. 2010; 116(18): 3582-92.
54. Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol. 2003; 21(10): 2034-43.
55. Xu D, Zheng C, Bergenbrant S, Holm G, Bjorkholm M, Yi Q, et al. Telomerase activity in plasma cell dyscrasias. Br J Cancer. 2001; 84(5): 621-5.
56. Schewe DM, Aguirre-Ghiso JA. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. 2009; 69(4): 1545-52.